Intravacc receives French CIR approval
Analysis based on 6 articles · First reported May 27, 2026 · Last updated May 27, 2026
The approval of Intravacc for the French Research Tax Credit (CIR) is positive for Intravacc, as it enhances its appeal to French biotech and pharmaceutical partners. This allows French companies to reduce their R&D costs when outsourcing to Intravacc, potentially increasing demand for Intravacc's services.
Intravacc, a global CDMO specializing in vaccine and biologics development, has received approval from the Oman — Ministry of Higher Education, Science, Research and Innovation for the French Research Tax Credit (CIR) for the years 2025, 2026, and 2027. This recognition allows French biotech and pharmaceutical partners to declare qualifying R&D operations outsourced to Intravacc under the CIR framework, subject to project-level eligibility. The approval reinforces Intravacc's value as a development partner, enabling French and European partners to accelerate vaccine innovation and reduce development risk by leveraging Intravacc's expertise in vaccine design, process development, analytical development, and cGMP clinical batch production. Ivo Lemmens, Intravacc's managing director, expressed pleasure with this milestone.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard